Merck's Latest Move: Why the Verona Deal Still Leaves Questions

Merck has acquired Verona Pharma for $10 billion, adding the FDA-approved COPD drug Ohtuvayre, with projected peak annual sales of $4 billion, as part of its strategy to address the looming $15-20 billion Keytruda patent cliff in 2028. However, this acquisition, even combined with Merck's broader pipeline, is deemed insufficient to fully offset the anticipated revenue erosion, as Ohtuvayre's contribution covers only approximately 20% of the potential decline. This significant remaining challenge is reflected in Merck's stock underperformance, down 16% year-to-date, signaling continued investor uncertainty regarding the company's comprehensive post-Keytruda growth strategy.

Analysis

Merck's acquisition of Verona Pharma for $10 billion is a direct strategic response to the impending 2028 patent expiration of its keystone drug, Keytruda, which is projected to create a $15-20 billion annual revenue gap. The deal secures Ohtuvayre, an FDA-approved COPD drug with estimated peak annual sales of $4 billion, thereby addressing only about 20% of the anticipated revenue erosion. This transaction is part of a broader, aggressive capital deployment strategy, including prior acquisitions of Acceleron ($11.5 billion) and Harpoon Therapeutics ($680 million), aimed at diversifying its portfolio. Despite these moves and a pipeline of 20 potential blockbusters, the market remains unconvinced of a comprehensive solution. This investor skepticism is reflected in the stock's significant underperformance, down 16% year-to-date against a 7% rise in the S&P 500, and its depressed valuation, with a trailing P/E ratio of approximately 11x compared to its historical average of 15x. The acquisition highlights both management's urgency and the sheer magnitude of the challenge, suggesting that the company's valuation will likely remain under pressure until a clearer path to post-2028 growth materializes.

Key Decisions for Investors

• Consider the Verona acquisition as an incremental positive but fundamentally insufficient to solve the Keytruda patent cliff, implying that Merck's risk profile remains elevated ahead of 2028.
• Recognize that the stock's current valuation discount to its historical average reflects deep-seated market doubt about its long-term growth, and a significant re-rating is unlikely without further transformative M&A or major pipeline successes.
• Monitor the execution and clinical progress of Merck's broader 20-drug pipeline, as successful commercialization from this portfolio is critical to closing the substantial remaining revenue gap.
• Investors should weigh the potential for a valuation floor given the depressed P/E ratio against the significant overhang from the Keytruda cliff and other headwinds like slowing Gardasil sales.